ASP1517 Phase 3 Clinical Trial - Long Term Study of Intermittent Oral Dosing of ASP1517 in Hemodialysis Chronic Kidney Disease Patients With Anemia Converted From ESA Treatment
Phase of Trial: Phase III
Latest Information Update: 13 Dec 2017
At a glance
- Drugs Roxadustat (Primary)
- Indications Anaemia
- Focus Registrational; Therapeutic Use
- Sponsors Astellas Pharma
- 07 Dec 2017 Status changed from active, no longer recruiting to completed.
- 08 Dec 2016 Status changed from recruiting to active, no longer recruiting.
- 25 Jul 2016 According to an Astellas Pharma media release, first patient has been treated in this study.